JP7727371B2 - うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 - Google Patents

うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Info

Publication number
JP7727371B2
JP7727371B2 JP2019531740A JP2019531740A JP7727371B2 JP 7727371 B2 JP7727371 B2 JP 7727371B2 JP 2019531740 A JP2019531740 A JP 2019531740A JP 2019531740 A JP2019531740 A JP 2019531740A JP 7727371 B2 JP7727371 B2 JP 7727371B2
Authority
JP
Japan
Prior art keywords
adm
antibody
seq
adrenomedullin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503013A (ja
JP2020503013A5 (enExample
Inventor
フォールス アドリアーン
Original Assignee
アドレノメト アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16206305.1A external-priority patent/EP3339324A1/en
Application filed by アドレノメト アクチェンゲゼルシャフト filed Critical アドレノメト アクチェンゲゼルシャフト
Publication of JP2020503013A publication Critical patent/JP2020503013A/ja
Publication of JP2020503013A5 publication Critical patent/JP2020503013A5/ja
Priority to JP2023009286A priority Critical patent/JP7892568B2/ja
Priority to JP2024143320A priority patent/JP2024170454A/ja
Application granted granted Critical
Publication of JP7727371B2 publication Critical patent/JP7727371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019531740A 2016-12-16 2017-12-18 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 Active JP7727371B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023009286A JP7892568B2 (ja) 2016-12-16 2023-01-25 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP2024143320A JP2024170454A (ja) 2016-12-16 2024-08-23 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16204847.4 2016-12-16
EP16204847 2016-12-16
EP16206305.1A EP3339324A1 (en) 2016-12-22 2016-12-22 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
EP16206305.1 2016-12-22
EP17197176 2017-10-18
EP17197176.5 2017-10-18
PCT/EP2017/083311 WO2018109228A1 (en) 2016-12-16 2017-12-18 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023009286A Division JP7892568B2 (ja) 2016-12-16 2023-01-25 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Publications (3)

Publication Number Publication Date
JP2020503013A JP2020503013A (ja) 2020-01-30
JP2020503013A5 JP2020503013A5 (enExample) 2021-02-04
JP7727371B2 true JP7727371B2 (ja) 2025-08-21

Family

ID=61148166

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019531740A Active JP7727371B2 (ja) 2016-12-16 2017-12-18 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP2023009286A Active JP7892568B2 (ja) 2016-12-16 2023-01-25 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP2024143320A Pending JP2024170454A (ja) 2016-12-16 2024-08-23 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023009286A Active JP7892568B2 (ja) 2016-12-16 2023-01-25 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP2024143320A Pending JP2024170454A (ja) 2016-12-16 2024-08-23 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Country Status (13)

Country Link
US (2) US20200299372A1 (enExample)
EP (1) EP3555130A1 (enExample)
JP (3) JP7727371B2 (enExample)
KR (3) KR20190120174A (enExample)
CN (2) CN110167962B (enExample)
AU (2) AU2017375049B2 (enExample)
BR (1) BR112019011713A2 (enExample)
CA (1) CA3046850A1 (enExample)
IL (2) IL322765A (enExample)
MX (1) MX2019007107A (enExample)
MY (1) MY208219A (enExample)
RU (1) RU2762059C2 (enExample)
WO (1) WO2018109228A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220227854A1 (en) * 2017-09-25 2022-07-21 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CA3168978A1 (en) * 2020-02-27 2021-09-02 Andreas Bergmann Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
US20210285949A1 (en) * 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
CN119072492A (zh) 2022-03-15 2024-12-03 艾德里诺医药公司 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂
KR20250040987A (ko) * 2022-07-20 2025-03-25 상하이 제유 파마슈티칼 컴퍼니 리미티드 항-아드레노메둘린 비중화 항체, 이의 제조 방법 및 응용

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533671A (ja) 2011-11-16 2014-12-15 アドレノメト アクチェンゲゼルシャフト 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP2014533672A (ja) 2011-11-16 2014-12-15 アドレノメト アクチェンゲゼルシャフト 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP2015501797A (ja) 2011-11-16 2015-01-19 アドレノメト アクチェンゲゼルシャフト 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2004097423A1 (en) 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2324059A4 (en) * 2008-07-01 2012-12-05 Cephalon Australia Vic Pty Ltd THERAPEUTIC ANTI-PAMP ANTIBODIES
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
BR112012032389A2 (pt) * 2010-06-18 2016-10-25 Brahms Gmbh biomarcadores para a previsão de câncer incidente
HRP20191771T1 (hr) * 2011-11-16 2019-12-27 Adrenomed Ag Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije
US9140696B2 (en) * 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
ES2494190T3 (es) * 2011-11-16 2014-09-15 Adrenomed Ag Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533671A (ja) 2011-11-16 2014-12-15 アドレノメト アクチェンゲゼルシャフト 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP2014533672A (ja) 2011-11-16 2014-12-15 アドレノメト アクチェンゲゼルシャフト 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP2015501797A (ja) 2011-11-16 2015-01-19 アドレノメト アクチェンゲゼルシャフト 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場

Also Published As

Publication number Publication date
KR20190120174A (ko) 2019-10-23
AU2017375049B2 (en) 2025-01-30
IL322765A (en) 2025-10-01
IL267282A (en) 2019-08-29
RU2019122135A (ru) 2021-01-18
JP2020503013A (ja) 2020-01-30
KR20240033285A (ko) 2024-03-12
CN110167962B (zh) 2024-06-07
AU2025202983A1 (en) 2025-05-22
MY208219A (en) 2025-04-24
WO2018109228A1 (en) 2018-06-21
EP3555130A1 (en) 2019-10-23
AU2017375049A1 (en) 2019-06-13
RU2021135712A (ru) 2021-12-30
JP2023052614A (ja) 2023-04-11
CN118767128A (zh) 2024-10-15
MX2019007107A (es) 2019-10-21
US20220041703A1 (en) 2022-02-10
RU2762059C2 (ru) 2021-12-15
CN110167962A (zh) 2019-08-23
KR20250084231A (ko) 2025-06-10
JP7892568B2 (ja) 2026-07-21
JP2024170454A (ja) 2024-12-10
BR112019011713A2 (pt) 2019-10-15
CA3046850A1 (en) 2018-06-21
US20200299372A1 (en) 2020-09-24
RU2019122135A3 (enExample) 2021-02-10

Similar Documents

Publication Publication Date Title
US12338281B2 (en) Anti-adrenomedullin antibodies and pharmaceutical compositions thereof
JP2024170454A (ja) うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP6321545B2 (ja) 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP6224608B2 (ja) 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP6321544B2 (ja) 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP6193872B2 (ja) 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
EP3339324A1 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
HK40111456A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
RU2857684C2 (ru) АНТИТЕЛО ПРОТИВ АДРЕНОМЕДУЛЛИНА (ADM), ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM не-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ ПРИ ВМЕШАТЕЛЬСТВЕ И ТЕРАПИИ ГИПЕРЕМИИ У ПАЦИЕНТА
EP4345109A1 (en) Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease
HK40007505A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
RU2854796C1 (ru) Связующее вещество против адреномедуллина (adm) для применения в терапии пациентов в состоянии шока
HK40007505B (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
KR20220145898A (ko) 쇼크 환자의 치료에 사용하기 위한 항-아드레노메둘린 (adm) 결합제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250808

R150 Certificate of patent or registration of utility model

Ref document number: 7727371

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150